TD BenchMark IHC/ISH and Special Stains Reagents

Device Roche Diagnostics Corporation
Total Payments
$1.1M
Transactions
914
Doctors
652
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $696,657 67 58
2019 $287,292 231 190
2018 $61,723 255 228
2017 $36,634 361 251

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $918,904 9 84.9%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,720 19 6.3%
Consulting Fee $34,960 11 3.2%
Food and Beverage $28,848 804 2.7%
Travel and Lodging $21,495 66 2.0%
Education $9,381 5 0.9%

Payments by Type

Research
$918,904
9 transactions
General
$163,403
905 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
RD005216 Roche Diagnostics Corporation $670,650 0
RD004121 Roche Diagnostics Corporation $117,874 0
RD003770 Roche Diagnostics Corporation $72,967 0
RD03770 Roche Diagnostics Corporation $44,700 0
RD005116 Roche Diagnostics Corporation $12,712 0

Top Doctors Receiving Payments for TD BenchMark IHC/ISH and Special Stains Reagents — Page 27

Doctor Specialty Location Total Records
, MD Anatomic Pathology & Clinical Pathology Stony Brook, NY $10.80 1
, M.D., PH.D Student in an Organized Health Care Education/Training Program Boston, MA $10.80 1
, M.D Anatomic Pathology Boston, MA $10.80 1

About TD BenchMark IHC/ISH and Special Stains Reagents

TD BenchMark IHC/ISH and Special Stains Reagents is a device associated with $1.1M in payments to 652 healthcare providers, recorded across 914 transactions in the CMS Open Payments database. The primary manufacturer is Roche Diagnostics Corporation.

Payment data is available from 2017 to 2020. In 2020, $696,657 was paid across 67 transactions to 58 doctors.

The most common payment nature for TD BenchMark IHC/ISH and Special Stains Reagents is "Unspecified" ($918,904, 84.9% of total).

TD BenchMark IHC/ISH and Special Stains Reagents is associated with 5 research studies, including "RD005216" ($670,650).